Free Trial

Scilex (SCLX) Competitors

Scilex logo
$7.00 +0.27 (+4.01%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$7.15 +0.15 (+2.14%)
As of 07:41 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SCLX vs. TLSA, IMAB, LFVN, ENTA, IPHA, ACOG, DERM, SPRO, DMAC, and NVCT

Should you be buying Scilex stock or one of its competitors? The main competitors of Scilex include Tiziana Life Sciences (TLSA), I-Mab (IMAB), Lifevantage (LFVN), Enanta Pharmaceuticals (ENTA), Innate Pharma (IPHA), Alpha Cognition (ACOG), Journey Medical (DERM), Spero Therapeutics (SPRO), DiaMedica Therapeutics (DMAC), and Nuvectis Pharma (NVCT). These companies are all part of the "pharmaceutical products" industry.

Scilex vs. Its Competitors

Tiziana Life Sciences (NASDAQ:TLSA) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Scilex has a consensus price target of $455.00, indicating a potential upside of 6,400.00%. Given Scilex's stronger consensus rating and higher probable upside, analysts plainly believe Scilex is more favorable than Tiziana Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tiziana Life Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Scilex
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Tiziana Life Sciences had 1 more articles in the media than Scilex. MarketBeat recorded 2 mentions for Tiziana Life Sciences and 1 mentions for Scilex. Scilex's average media sentiment score of 1.89 beat Tiziana Life Sciences' score of 0.63 indicating that Scilex is being referred to more favorably in the news media.

Company Overall Sentiment
Tiziana Life Sciences Positive
Scilex Very Positive

Tiziana Life Sciences has a beta of -0.05, meaning that its stock price is 105% less volatile than the S&P 500. Comparatively, Scilex has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.

69.7% of Scilex shares are owned by institutional investors. 39.8% of Tiziana Life Sciences shares are owned by insiders. Comparatively, 7.9% of Scilex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tiziana Life Sciences has higher earnings, but lower revenue than Scilex.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tiziana Life SciencesN/AN/A-$11.86MN/AN/A
Scilex$56.59M0.86-$72.81M-$29.02-0.24

Tiziana Life Sciences has a net margin of 0.00% compared to Scilex's net margin of -146.93%.

Company Net Margins Return on Equity Return on Assets
Tiziana Life SciencesN/A N/A N/A
Scilex -146.93%N/A -82.65%

Summary

Scilex beats Tiziana Life Sciences on 7 of the 12 factors compared between the two stocks.

Get Scilex News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCLX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCLX vs. The Competition

MetricScilexMED IndustryMedical SectorNASDAQ Exchange
Market Cap$46.78M$2.90B$5.51B$9.31B
Dividend YieldN/A2.46%4.25%4.09%
P/E Ratio-0.2420.3628.1919.69
Price / Sales0.86299.07442.3499.85
Price / CashN/A42.3835.5357.53
Price / Book-0.257.768.235.67
Net Income-$72.81M-$55.11M$3.23B$257.51M
7 Day Performance7.86%0.19%-0.57%-0.16%
1 Month Performance50.86%10.80%6.66%9.89%
1 Year Performance-89.74%-0.68%27.11%15.08%

Scilex Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCLX
Scilex
2.5535 of 5 stars
$7.00
+4.0%
$455.00
+6,400.0%
-89.8%$46.78M$56.59M-0.2480Positive News
TLSA
Tiziana Life Sciences
1.1693 of 5 stars
$1.53
+1.3%
N/A+85.2%$176.44MN/A0.008
IMAB
I-Mab
2.8522 of 5 stars
$2.09
-2.8%
$6.00
+187.1%
+31.9%$175.57M$3.89M0.00380Gap Down
LFVN
Lifevantage
4.2436 of 5 stars
$13.59
-0.9%
$30.50
+124.4%
+97.8%$172.71M$200.16M17.82260News Coverage
ENTA
Enanta Pharmaceuticals
3.755 of 5 stars
$7.65
-3.0%
$18.00
+135.3%
-56.1%$168.66M$67.64M0.00160News Coverage
IPHA
Innate Pharma
2.8094 of 5 stars
$1.79
-1.6%
$11.00
+514.5%
-16.3%$167.76M$21.77M0.00220News Coverage
ACOG
Alpha Cognition
1.733 of 5 stars
$11.24
+7.4%
$20.00
+77.9%
N/A$167.65MN/A0.00N/A
DERM
Journey Medical
2.4054 of 5 stars
$7.11
+0.1%
$9.50
+33.6%
+21.8%$165.40M$56.13M0.0090
SPRO
Spero Therapeutics
3.9283 of 5 stars
$2.90
-0.3%
$5.00
+72.4%
+64.7%$162.70M$47.98M0.00150
DMAC
DiaMedica Therapeutics
1.1812 of 5 stars
$3.63
-3.5%
$8.00
+120.4%
+17.4%$161.24MN/A0.0020High Trading Volume
NVCT
Nuvectis Pharma
3.3264 of 5 stars
$7.85
+4.1%
$17.00
+116.6%
+18.4%$157.54MN/A0.008

Related Companies and Tools


This page (NASDAQ:SCLX) was last updated on 7/17/2025 by MarketBeat.com Staff
From Our Partners